Sunosi (solriamfetol) coverage for excessive daytime sleepiness
Policy covers Sunosi (solriamfetol) for adults (>=18 years) with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea (OSA) under specified prior-authorization clinical criteria; other indications are considered investigational/not covered. Scope: Medicaid.
No material clinical/coverage changes to policy.
Coverage Summary
Sunosi (solriamfetol) is covered with prior authorization under this Medicaid policy for adults ≥18 years with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea (OSA) when specified clinical criteria are met (FDA‑approved indication, prescriber specialty, documented diagnostic confirmation, required prior therapies or documented intolerance/contraindication, and CPAP requirements for OSA). All other indications are considered experimental/investigational and are not covered.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.